24HourWire

24HourWire

News from all angles

STAT News Center

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

Redirecting to STAT News in 3 seconds...

Read Now → Explore 24HourWire

Share this story with your network